Kiora Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Net Income (Loss) per Share - Basic and Diluted (Details)

Net Income (Loss) per Share - Basic and Diluted (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted-average unvested restricted common stock that has been issued and is subject to forfeiture (in shares)	24,094	7,478	24,094	7,478
Anti-dilutive shares excluded from the calculation of net loss per share (in shares)			6,909,062	1,585,672
Common Stock Warrants, Excluding Pre-funded Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from the calculation of net loss per share (in shares)			6,197,993	1,457,054
Employee Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from the calculation of net loss per share (in shares)			88,993	23,505
Restricted Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from the calculation of net loss per share (in shares)			24,094	7,478
Preferred Stock, as Converted into Common Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from the calculation of net loss per share (in shares)			42,426	95,956
Common Stock Reserved for Future Issuance
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from the calculation of net loss per share (in shares)			555,556	1,680